Head to Head Contrast: Pulmonx (NASDAQ:LUNG) & P3 Health Partners (NASDAQ:PIII)

Pulmonx (NASDAQ:LUNG) and P3 Health Partners (NASDAQ:PIII) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, analyst recommendations, earnings, valuation and risk.

Profitability

This table compares Pulmonx and P3 Health Partners’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulmonx	-60.09%	-92.94%	-39.80%
P3 Health Partners	-8.57%	-302.33%	-19.99%

Institutional & Insider Ownership

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are held by institutional investors. 6.8% of Pulmonx shares are held by company insiders. Comparatively, 10.9% of P3 Health Partners shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Pulmonx has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500. Comparatively, P3 Health Partners has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Pulmonx and P3 Health Partners, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1	2	4	0	2.43
P3 Health Partners	1	2	1	0	2.00

Pulmonx currently has a consensus price target of $5.58, indicating a potential upside of 346.67%. P3 Health Partners has a consensus price target of $14.00, indicating a potential upside of 24.67%. Given Pulmonx’s stronger consensus rating and higher probable upside, research analysts clearly believe Pulmonx is more favorable than P3 Health Partners.

Valuation & Earnings

This table compares Pulmonx and P3 Health Partners”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50 million	0.58	-$54.00 million	($1.30)	-0.96
P3 Health Partners	$1.46 billion	0.06	-$147.95 million	($38.60)	-0.29

Pulmonx has higher earnings, but lower revenue than P3 Health Partners. Pulmonx is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Summary

Pulmonx beats P3 Health Partners on 8 of the 14 factors compared between the two stocks.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

About P3 Health Partners

P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.